Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 222

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Worldwide Collaborative Observational Study and Meta‐Analysis on Allogenic Leukocyte Immunotherapy for Recurrent Spontaneous Abortion1

The Recurrent Miscarriage Immunotherapy Trialists Group, Coulam, C.B., Clark, D.A., Collins, J., Scott, J.R., Schlesselman, J.S., Aoki, K., Carp, H.J.A., Cauchi, M.N., Lim, D., Christiansen, O.B., Grunnet, N., Cowchock, S., Smith, J.B., Daya, S., Gatenby, P., Cameron, K., Gill, T.J., Hin, H.O., Georgieva, R., Belchev, D., Kilpatrick, D.C., Liston, W., Mowbray, J.F., Underwood, J., Parazzini, F., Crosignani, P.G., Rezenkoff, M.F., Koyama, F. Saji·1994·American Journal of Reproductive Immunology

Abstract

PROBLEM: Recurrent spontaneous abortion (RSA) is a common complication of pregnancy for which there is no known cure. Therefore, effective treatment is needed. Published results from controlled clinical trials of allogeneic leukocyte immunization of women suffering from RSA have given conflicting results. To address this controversy, the international raw data of all patients who had been entered into clinical trials that included a control group were collected and analyzed. The primary question to be answered was whether alloimmune stimulation of the female partner improves the subsequent live birth rate. METHODS: Fifteen clinical centers were identified worldwide because they controlled appropriate raw data. Consequently, nine randomized trials (seven double‐blinded) were evaluated independently by two separate data analysis teams to assure conclusions were robust. One team also compared randomized trials to the results of six nonrandomized cohort‐controlled studies to test for bias in nonrandomized trials. Factors predicting successful live births among couples with RSA were evaluated by logistic regression. RESULTS: Although the two independent analyses made use of different definitions and utilized different statistical methods, the results of both were similar. The live birth ratios (ratio of live births in treatment and control groups) with 95% confidence intervals (CI) were 1.16 (CI, 1.01‐1.34, P = 0.031) and 1.21 (CI, 1.04‐1.37, P = 0.024), respectively. The absolute differences in live birth rates between treatment and control groups were 8% and 10% in respective analyses. Results in randomized and nonrandomized trials were surprisingly similar despite significant differences in composition of control and treatment groups. Live birth rates were lower with older female partners, more than five abortions, with a positive ANA or with positive anticardiolipin antibodies. Live birth rates were higher if the female partner had prior to treatment serum antibodies to paternal leukocytes or converted from negative to positive with immunization. Approximately 0.5% of controls and 2.1% of treated patients experience side effects for a 1.6% treatment related effect. There was no evidence of an increased risk of adverse effects on the fetus. CONCLUSIONS: Two independent analyses of worldwide data on allogeneic leukocyte immunization for treatment of RSA suggest that alloimmunization may be an effective treatment. The treatment effect appears, however, to be small, and the data indicate that immunotherapy helps only 8% to 10% of affected couples. A current lack of diagnostic tests defining patients who most likely would benefit from immunotherapy, precludes the identification of a patient population that would benefit most from such treatment. The efficacy of treatment in such a subgroup could be expected to increase and could be of sufficient magnitude to allow the determination of more effective immunization protocols. This study does not exclude the possibility of a partial correction of a widely prevalent immunology defect by immunotherapy. The presence of such a defect would indicate a need for more effective therapy. The unexplained variation in pregnancy success rates of control groups among centers continues to present a statistical problem, limiting the statistical evaluation of retroactively obtained data.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1600-0897.1994.tb01095.x

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 222

Metadata

Authors
The Recurrent Miscarriage Immunotherapy Trialists Group, Coulam, C. B., Clark, D. A., Collins, J., Scott, J. R., Schlesselman, J. S., Aoki, K., Carp, H. J. A., Cauchi, M. N., Lim, D., Christiansen, O. B., Grunnet, N., Cowchock, S., Smith, J. B., Daya, S., Gatenby, P., Cameron, K., Gill, T. J., Hin, H. O., Georgieva, R., Belchev, D., Kilpatrick, D. C., Liston, W., Mowbray, J. F., Underwood, J., Parazzini, F., Crosignani, P. G., Rezenkoff, M. F., & Koyama, F. S.
Venue
American Journal of Reproductive Immunology
Publisher
Wiley
Published
1994-09
Volume
32
Issue
2
Pages
55-72
ISSN
  • 0271-7352 (ISSN-L)
  • 1046-7408
  • 1600-0897
OpenAlex
W2014270110
Cited by
222
References
1
FWCI
5.59
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Worldwide Collaborative Observational Study and Meta‐Analysis on Allogenic Leukocyte Immunotherapy for Recurrent Spontaneous Abortion1. https://app.cochat.ai/papers/10.1111/j.1600-0897.1994.tb01095.x
The paper
The Recurrent Miscarriage Immunotherapy Trialists Group, Coulam, C. B., Clark, D. A., Collins, J., Scott, J. R., Schlesselman, J. S., Aoki, K., Carp, H. J. A., Cauchi, M. N., Lim, D., Christiansen, O. B., Grunnet, N., Cowchock, S., Smith, J. B., Daya, S., Gatenby, P., Cameron, K., Gill, T. J., Hin, H. O., . . . Koyama, F. S. (1994). Worldwide Collaborative Observational Study and Meta‐Analysis on Allogenic Leukocyte Immunotherapy for Recurrent Spontaneous Abortion1. American Journal of Reproductive Immunology. https://doi.org/10.1111/j.1600-0897.1994.tb01095.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.